ArticleCell reports2018
Clinical and Genomic Crosstalk between Glucocorticoid Receptor and Estrogen Receptor α In Endometrial Cancer.
Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 75 citations in OpenAlex.
- Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer.Cancer research · 2026Review
- TENT5C functions as a corepressor in the ligand-bound glucocorticoid receptor and estrogen receptor α complexes.The FEBS journal · 2025Article
- Genetic insights into the relationship between anti-inflammatory drug target genes and oral diseases.Inflammopharmacology · 2025Article
- Androgen receptor-mediated assisted loading of the glucocorticoid receptor modulates transcriptional responses in prostate cancer cells.Genome research · 2025Article
- Psychological stress-activated NR3C1/NUPR1 axis promotes ovarian tumor metastasis.Acta pharmaceutica Sinica. B · 2025Article
- Endometrial tumorigenesis involves epigenetic plasticity demarcating non-coding somatic mutations and 3D-genome alterations.Genome biology · 2025Article
- Expression and prognosis of NR3C1 in uterine corpus endometrial carcinoma based on multiple datasets.Discover oncology · 2025Article
- Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models.Journal of gynecologic oncology · 2025Article
- Divergent ERα co-factor landscapes in gynecological cancers: implications for disease progression and therapy.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2025Review
- Effects of anesthetics on development of gynecological cancer.Frontiers in cell and developmental biology · 2025Review
- Association between chronic stress-related amygdala metabolic activity and lymph node metastasis in endometrial cancer.Scientific reports · 2024Article
- Discovery of a glucocorticoid receptor (GR) activity signature correlates with immune cell infiltration in adrenocortical carcinoma.Journal for immunotherapy of cancer · 2023Article
- Estrogen Receptor Signaling in Breast Cancer.Cancers · 2023Review
- Cadmium, Lead, Chronic Physiological Stress and Endometrial Cancer: How Environmental Policy Can Alter the Exposure of At-Risk Women in the United States.Healthcare (Basel, Switzerland) · 2023Article
- Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?Frontiers in endocrinology · 2023Article
- Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line.Scientific reports · 2022Article
- A New Perspective on Thyroid Hormones: Crosstalk with Reproductive Hormones in Females.International journal of molecular sciences · 2022Review
- The Flavonoid Baicalein Negatively Regulates Progesterone Target Genes in the UterusJournal of natural products · 2022Article
- Article
- Intestinal epithelial glucocorticoid receptor promotes chronic inflammation-associated colorectal cancer.JCI insight · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Steroid hormone receptors are simultaneously active in many tissues and are capable of altering each other's function. Estrogen receptor α (ER) and glucocorticoid receptor (GR) are expressed in the uterus, and their ligands have opposing effects on uterine growth. In endometrial tumors with high ER expression, we surprisingly found that expression of GR is associated with poor prognosis. Dexamethasone reduced normal uterine growth in vivo; however, this growth inhibition was abolished in estrogen-induced endometrial hyperplasia. We observed low genomic-binding site overlap when ER and GR are induced with their respective ligands; however, upon simultaneous induction they co-occupy more sites. GR binding is altered significantly by estradiol with GR recruited to ER-bound loci that become more accessible upon estradiol induction. Gene expression responses to co-treatment were more similar to estradiol but with additional regulated genes. Our results suggest phenotypic and molecular interplay between ER and GR in endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.